{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10"],"submitter":["Canuti M"],"pubmed_abstract":["Specific immune suppression types have been associated with a greater risk of severe COVID-19 disease and death. We analyzed data from patients >17 years that were hospitalized for COVID-19 at the \"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico\" in Milan (Lombardy, Northern Italy). The study included 1727 SARS-CoV-2-positive patients (1,131 males, median age of 65 years) hospitalized between February 2020 and November 2022. Of these, 321 (18.6%, CI: 16.8-20.4%) had at least one condition defining immune suppression. Immune suppressed subjects were more likely to have other co-morbidities (80.4% vs. 69.8%, <i>p</i> < 0.001) and be vaccinated (37% vs. 12.7%, <i>p</i> < 0.001). We evaluated the contribution of immune suppression to hospitalization during the various stages of the e"],"journal":["Frontiers in medicine"],"pagination":["1260950"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10513414"],"repository":["biostudies-literature"],"pubmed_title":["The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic."],"pmcid":["PMC10513414"],"pubmed_authors":["Bobbio C","Maura S","Gianluca Z","Bandera A","Margherita O","Natalia S","Simona B","Valter M","Angelica C","Grazia Eliana C","Mariele P","Canuti M","Davide M","Elisa F","Paola S","Nicola M","Muheberimana T","Costantino G","Alice R","Diletta M","Alice F","COVID-19 Network Study Group","Alice D","Canetta C","Letizia M","Baldi SL","Chiara B","Barbara F","Michele De C","Cinzia Maria H","Costanza M","Villa S","Giulia R","Luigia S","Giulia V","Francesca F","Giuseppe L","Barbara V","Stefano S","Giuseppe A","Carlo AP","Monti MC","Daniele P","Marta Di P","Mirta C","Agata B","Luca V","Sofia M","Carlotta C","Teresa I","Giulia C","Blasi F","Clara M","Eleonora T","Filippo B","Martina C","Irene M","Irena R","Laura B","Laura A","Silvano B","Ludovico F","Laura C","Muscatello A","Laura R","Leonardo T","Tiziano L","Monica S","Emanuele P","Agnese C","Giuliana F","Maria P","Maria M","Nathalie I","Valentina F","Giacomo G","Erica P","Peyvandi F","Raffaella R","Silvia A","Andrea P","Silvia G","Maria Teresa C","Silvia D","Andrea L","Alessia Antonella G","Riccardo U","Arianna L","Gori A","Rosaria B","Marta M","Marco V","Raviglione MC","Roberta G","Aliberti S","Marco P","Nobili A","Silvia Della F","Giorgio C","Giorgio B","Serena L","Christian F","Valeria C","Rosa L","Roberta M","Andrea G","Marco F","Marco M","Valeria F","Anna Ludovica F","Nadia B","Valerie M","Valeria P","Valeria R","Arturo C","Matteo C","Matteo B","Alessandro G","Annalisa C","Tettamanti M","Angelo R","Igor M"],"additional_accession":[]},"is_claimable":false,"name":"The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.","description":"Specific immune suppression types have been associated with a greater risk of severe COVID-19 disease and death. We analyzed data from patients >17 years that were hospitalized for COVID-19 at the \"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico\" in Milan (Lombardy, Northern Italy). The study included 1727 SARS-CoV-2-positive patients (1,131 males, median age of 65 years) hospitalized between February 2020 and November 2022. Of these, 321 (18.6%, CI: 16.8-20.4%) had at least one condition defining immune suppression. Immune suppressed subjects were more likely to have other co-morbidities (80.4% vs. 69.8%, <i>p</i> < 0.001) and be vaccinated (37% vs. 12.7%, <i>p</i> < 0.001). We evaluated the contribution of immune suppression to hospitalization during the various stages of the e","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-05-29T16:36:24.784Z","creation":"2025-05-29T16:36:24.784Z"},"accession":"S-EPMC10513414","cross_references":{"pubmed":["37746083"],"doi":["10.3389/fmed.2023.1260950"]}}